<DOC>
	<DOC>NCT00150553</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of SPD417 in treating bipolar manic symptoms, when given once daily in the evening vs. twice daily.</brief_summary>
	<brief_title>Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>DSMIV criteria for bipolar I disorder Screen YMRS score =&gt; 16 Women of childbearing potential agree to take adequate precautions against contraception Hospitalization required for treatment of psychiatric symptoms Patients who meet DSMIV for ultrarapid cycling History of serious suicide attempt requiring medical intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
</DOC>